Ion Pair Liquid Crystal Formulations for Long-Acting Injectables of Poorly Soluble Drugs
Summary
USPTO published patent application US20260097044A1 by FORDOZ PHARMA Corp. disclosing ion pair liquid crystal formulations designed to solubilize poorly soluble drugs and enable controlled release via parenteral administration. The application covers ion pairs including Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine incorporated into liquid crystal vehicles.
What changed
USPTO published patent application US20260097044A1 by FORDOZ PHARMA Corp. disclosing ion pair liquid crystal formulations designed to solubilize poorly soluble drugs and enable controlled release via parenteral administration. The application specifically covers ion pairs including Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine incorporated into liquid crystal vehicles for injectable drug delivery.
Pharmaceutical companies and drug developers should monitor this application as it indicates potential competitive activity in poorly soluble drug formulation using liquid crystal technology. Competitors developing long-acting injectable products may need to assess freedom-to-operate implications for their own formulation programs.
What to do next
- Monitor competitor patent activity in long-acting injectable formulation space
- Review internal R&D programs for freedom-to-operate implications
- Ensure trade secret protections for proprietary formulation technologies
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS
Application US20260097044A1 Kind: A1 Apr 09, 2026
Assignee
FORDOZ PHARMA Corp.
Inventors
Yuan Chen, Sydney Ugwu, Yiwen Wang, James He
Abstract
This application discloses a method to solubilize poorly soluble drugs in a liquid crystal vehicle for long-acting injectables. Poorly soluble acidic drugs-hydrophobic basic compounds ion pairs are incorporated into liquid crystal vehicles to solubilize and slowly release the drug after parenteral administration. Ion pairs such as Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine are incorporated into liquid crystal vehicles to solubilize and control release the drugs.
CPC Classifications
A61K 31/5415 A61K 31/198 A61K 31/445 A61K 31/505 A61K 31/519 A61K 47/10 A61K 47/14 A61K 47/20 A61K 47/22 A61K 47/24
Filing Date
2025-09-24
Application No.
19338302
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.